Patents Assigned to Procell Therapeutics Inc.
-
Patent number: 9694087Abstract: The present invention relates to an improved macromolecule transduction domain (MTD), which facilitates permeating the cell membrane of a biologically active molecule, having enhanced cell permeability. Specifically, an improved MTD according to the present invention, compared to an existing MTD, can transmit various types of biologically active molecule from inside the body and inside a test tube more effectively, and thus can be effectively used in a method to genetically alter a biologically active molecule so as to have cell permeability or in a method to transport a biologically active molecule into a cell, or the like. Additionally, the improved MTD can be very useful in development of new drugs and incrementally modified drugs as uses of the improved MTD are possible in drug delivery systems, recombinant protein vaccines or DNA/RNA therapeutic agents, gene or protein therapies, and pharmacologically or medically useful protein production or medical, pharmacological and pharmaceutical compositions.Type: GrantFiled: January 15, 2016Date of Patent: July 4, 2017Assignee: PROCELL THERAPEUTICS INC.Inventors: Ki Deok Shin, Kang Jin Lee, Sunny Lim, Byung Kyu Lee, Jong Rae Kim
-
Patent number: 9259481Abstract: The present invention relates to an improved macromolecule transduction domain (MTD), which facilitates permeating the cell membrane of a biologically active molecule, having enhanced cell permeability. Specifically, an improved MTD according to the present invention, compared to an existing MTD, can transmit various types of biologically active molecule from inside the body and inside a test tube more effectively, and thus can be effectively used in a method to genetically alter a biologically active molecule so as to have cell permeability or in a method to transport a biologically active molecule into a cell, or the like. Additionally, the improved MTD can be very useful in development of new drugs and incrementally modified drugs as uses of the improved MTD are possible in drug delivery systems, recombinant protein vaccines or DNA/RNA therapeutic agents, gene or protein therapies, and pharmacologically or medically useful protein production or medical, pharmacological and pharmaceutical compositions.Type: GrantFiled: November 23, 2012Date of Patent: February 16, 2016Assignee: Procell Therapeutics Inc.Inventors: Ki Deok Shin, Kang Jin Lee, Sunny Lim, Byung Kyu Lee, Jong Rae Kim
-
Patent number: 9040477Abstract: The present invention discloses novel macromolecule transduction domain (MTD) peptides which facilitate the traverse of a biologically active molecule across the cell membrane. Also disclosed are polynucleotides encoding the MTD peptides, methods of identifying the MTD peptides; methods of genetically engineering a biologically active molecule to have cell permeability by using the MTD peptides, methods of importing a biologically active molecule into a cell by using the MTD peptides, and uses thereof.Type: GrantFiled: November 27, 2013Date of Patent: May 26, 2015Assignee: PROCELL THERAPEUTICS INC.Inventors: Dae Woong Jo, Jae Sun Ko, Jin Sook Kim, Kyung Mi Park, Jin Kyung Song, Jung Hee Lim, Thi Thuy Nga Do, Thi Lan Phuong Do, Minh Tam Duong
-
Publication number: 20140329737Abstract: The present invention relates to an improved macromolecule transduction domain (MTD), which facilitates permeating the cell membrane of a biologically active molecule, having enhanced cell permeability. Specifically, an improved MTD according to the present invention, compared to an existing MTD, can transmit various types of biologically active molecule from inside the body and inside a test tube more effectively, and thus can be effectively used in a method to genetically alter a biologically active molecule so as to have cell permeability or in a method to transport a biologically active molecule into a cell, or the like. Additionally, the improved MTD can be very useful in development of new drugs and incrementally modified drugs as uses of the improved MTD are possible in drug delivery systems, recombinant protein vaccines or DNA/RNA therapeutic agents, gene or protein therapies, and pharmacologically or medically useful protein production or medical, pharmacological and pharmaceutical compositions.Type: ApplicationFiled: November 23, 2012Publication date: November 6, 2014Applicant: Procell Therapeutics Inc.Inventors: Ki Deok Shin, Kang Jin Lee, Sunny Lim, Byung Kyu Lee, Jong Rae Kim
-
Publication number: 20140186379Abstract: The present invention discloses novel macromolecule transduction domain (MTD) peptides which facilitate the traverse of a biologically active molecule across the cell membrane. Also disclosed are polynucleotides encoding the MTD peptides, methods of identifying the MTD peptides; methods of genetically engineering a biologically active molecule to have cell permeability by using the MTD peptides, methods of importing a biologically active molecule into a cell by using the MTD peptides, and uses thereof.Type: ApplicationFiled: November 27, 2013Publication date: July 3, 2014Applicant: PROCELL THERAPEUTICS INC.Inventors: Dae Woong JO, Jae Sun Ko, Jin Sook Kim, Kyung Mi Park, Jin Kyung Song, Jung Hee Lim, Thi Thuy Nga Do, Thi Lan Phuong Do, Minh Tam Duong
-
Patent number: 8629097Abstract: The present invention discloses novel macromolecule transduction domain (MTD) peptides which facilitate the traverse of a biologically active molecule across the cell membrane. Also disclosed are polynucleotides encoding the MTD peptides, methods of identifying the MTD peptides; methods of genetically engineering a biologically active molecule to have cell permeability by using the MTD peptides, methods of importing a biologically active molecule into a cell by using the MTD peptides, and uses thereof.Type: GrantFiled: January 29, 2008Date of Patent: January 14, 2014Assignee: Procell Therapeutics Inc.Inventors: Dae Woong Jo, Jae Sun Ko, Jin Sook Kim, Kyung Mi Park, Jin Kyung Song, Jung Hee Lim, Thi Thuy Nga Do, Thi Lan Phuong Do, Minh Tam Duong
-
Patent number: 8586544Abstract: The present invention relates to a cell-permeable endostatin recombinant protein in which a macromolecule transduction domain (MTD) is fused to an angiogenesis inhibitor (angiogenesis inhibitor) endostatin; a polynucleotide encoding the cell-permeable endostatin recombinant protein; an expression vector for the cell-permeable endostatin recombinant protein; and a pharmacological composition for an anti-cancer preparation with improved inhibitory activity against angiogenesis in cancer, which contains the cell-permeable endostatin recombinant protein as an active component.Type: GrantFiled: April 3, 2009Date of Patent: November 19, 2013Assignees: Procell Therapeutics Inc.Inventors: Daewoong Jo, Jong Min Lee, Kyoungho Park, Minh Tam Duong
-
Patent number: 8470971Abstract: Disclosed are a cell-permeable p53 recombinant protein in which a macromolecule transduction domain (MTD) is fused to the tumor suppressor p53, a polynucleotide encoding the same, a recombinant expression vector for producing the same, and a pharmaceutical composition of the treatment of cancer, comprising the same. Having high cell permeability, the p53 recombinant protein is effectively transduced into cells so that the tumor suppressor p53 can be translocated into cell nuclei. Within nuclei, p53 inhibits the formation of cyclin-CDK complexes to halt the cell cycle, thus suppressing excessive cell proliferation and inducing apoptosis of tumor cells. Therefore, the p53 recombinant protein can be useful as an anticancer agent in the treatment of various cancers.Type: GrantFiled: December 2, 2009Date of Patent: June 25, 2013Assignee: Procell Therapeutics Inc.Inventors: Daewoong Jo, Jung-Hee Lim
-
Patent number: 8450279Abstract: The present invention discloses cell permeable Nm23 recombinant proteins where a macromolecule transduction domain (MTD) is fused to a metastasis suppressor Nm23. Also disclosed are polynucleotides encoding the cell permeable Nm23 recombinant proteins, an expression vector containing the cell permeable Nm23 recombinant protein, and a pharmaceutical composition for preventing metastasis which contains the cell permeable Nm23 recombinant protein as an effective ingredient. The cell permeable Nm23 recombinant proteins of the present invention can induce KSR phosphorylation and inactivation and inhibit Ras-mediated MAPK cascade by efficiently introducing a metastasis suppressor Nm23 into a cell. Therefore, the cell permeable Nm23 recombinant proteins of the present invention can be effectively used as an anti-metastatic agent capable of preventing cancer metastasis by inhibiting the proliferation, differentiation and migration of cancer cells.Type: GrantFiled: September 4, 2008Date of Patent: May 28, 2013Assignee: Procell Therapeutics Inc.Inventors: Daewoong Jo, Thi Thuy Nga Do, Kisuk Park
-
Patent number: 8445443Abstract: The present invention discloses cell permeable p18 recombinant proteins where a macromolecule transduction domain (MTD) is fused to a tumor suppressor p18. Also disclosed are polynucleotides encoding the cell permeable p18 recombinant proteins, an expression vector containing the cell permeable p18 recombinant protein, and a pharmaceutical composition for treating p18 deficiency or failure which contains the cell permeable p18 recombinant protein as an effective ingredient. The cell permeable p18 recombinant proteins of the present invention are capable of efficiently introducing a haploinsufficient tumor suppressor p18 into a cell, and thus, can activate cell signaling mechanisms involved in the activation of ATM and p53 that induce cell cycle arrest and apoptosis in response to DNA damage or oncogenic signals. Therefore, the cell permeable p18 recombinant proteins of the present invention can be effectively used as an anticancer agent.Type: GrantFiled: September 4, 2008Date of Patent: May 21, 2013Assignee: Procell Therapeutics Inc.Inventors: Daewoong Jo, Seolhwa Kim, Jung-Hee Lim, Kisuk Park, Se-Eun Kang
-
Publication number: 20120122796Abstract: Disclosed are a cell-permeable p53 recombinant protein in which a macromolecule transduction domain (MTD) is fused to the tumor suppressor p53, a polynucleotide encoding the same, a recombinant expression vector for producing the same, and a pharmaceutical composition of the treatment of cancer, comprising the same. Having high cell permeability, the p53 recombinant protein is effectively transduced into cells so that the tumor suppressor p53 can be translocated into cell nuclei. Within nuclei, p53 inhibits the formation of cyclin-CDK complexes to halt the cell cycle, thus suppressing excessive cell proliferation and inducing apoptosis of tumor cells. Therefore, the p53 recombinant protein can be useful as an anticancer agent in the treatment of various cancers.Type: ApplicationFiled: December 2, 2009Publication date: May 17, 2012Applicant: PROCELL THERAPEUTICS INC.Inventors: Daewoong Jo, Jung-Hee Lim
-
Publication number: 20120095188Abstract: The present invention relates to a reprogramming transcription factor recombinant protein in which a macromolecule transduction domain (MTD) is fused to a reprogramming transcription factor to obtain cell permeability. The present invention also relates to a polynucleotide for coding said reprogramming transcription factor recombinant protein and to an expression vector of said cell-permeable reprogramming transcription factor recombinant protein. Treating a somatic cell with the cell-permeable reprogramming transcription factor recombinant protein induces the reprogramming of the stem cell-specific gene of the somatic cell, and thus can be effectively used in the establishment of an induced pluripotent stem cell (iPS cell) having characteristics similar to those of an embryonic stem cell in terms of morphology and genetics.Type: ApplicationFiled: March 12, 2010Publication date: April 19, 2012Applicant: PROCELL THERAPEUTICS INC.Inventors: Daewoong Jo, Jung-Hee Lim, Jungeun Kim, Sooyoung Jeong, Inhee Jung
-
Patent number: 8158415Abstract: The present invention discloses cell permeable Nanog and Oct4 recombinant proteins that comprise a kaposi fibroblast growth factor 4 (kFGF4)-derived macromolecule transduction domain (MTD). Also disclosed are polynucleotides encoding the cell permeable Nanog and Oct4 recombinant proteins, a method of increasing self-renewal and suppressing differentiation of stem cells by treating the cells in combination with the cell permeable Nanog and Oct4 recombinant proteins, and the combined use of the cell permeable Nanog and Oct4 recombinant proteins for increasing self-renewal and suppressing differentiation of stem cells.Type: GrantFiled: February 27, 2008Date of Patent: April 17, 2012Assignee: Procell Therapeutics Inc.Inventors: Dae Woong Jo, Jin Sook Kim, Yun Kyung Park
-
Publication number: 20110092441Abstract: The present invention relates to a cell-permeable endostatin recombinant protein in which a macromolecule transduction domain (MTD) is fused to an angiogenesis inhibitor (angiogenesis inhibitor) endostatin; a polynucleotide encoding the cell-permeable endostatin recombinant protein; an expression vector for the cell-permeable endostatin recombinant protein; and a pharmacological composition for an anti-cancer preparation with improved inhibitory activity against angiogenesis in cancer, which contains the cell-permeable endostatin recombinant protein as an active component.Type: ApplicationFiled: April 3, 2009Publication date: April 21, 2011Applicants: PROCELL THERAPEUTICS INC, JO DaewoongInventors: Daewoong Jo, Jong Min Lee, Kyoungho Park, Minh Tam Duong
-
Publication number: 20100323971Abstract: The present invention discloses cell permeable Nm23 recombinant proteins where a macromolecule transduction domain (MTD) is fused to a metastasis suppressor Nm23. Also disclosed are polynucleotides encoding the cell permeable Nm23 recombinant proteins, an expression vector containing the cell permeable Nm23 recombinant protein, and a pharmaceutical composition for preventing metastasis which contains the cell permeable Nm23 recombinant protein as an effective ingredient. The cell permeable Nm23 recombinant proteins of the present invention can induce KSR phosphorylation and inactivation and inhibit Ras-mediated MAPK cascade by efficiently introducing a metastasis suppressor Nm23 into a cell. Therefore, the cell permeable Nm23 recombinant proteins of the present invention can be effectively used as an anti-metastatic agent capable of preventing cancer metastasis by inhibiting the proliferation, differentiation and migration of cancer cells.Type: ApplicationFiled: September 4, 2008Publication date: December 23, 2010Applicant: PROCELL THERAPEUTICS INC.Inventors: Daewoong Jo, Thi Thuy Nga Do, Kisuk Park
-
Publication number: 20100305041Abstract: The present invention discloses cell permeable p18 recombinant proteins where a macromolecule transduction domain (MTD) is fused to a tumor suppressor p18. Also disclosed are polynucleotides encoding the cell permeable p18 recombinant proteins, an expression vector containing the cell permeable p18 recombinant protein, and a pharmaceutical composition for treating p18 deficiency or failure which contains the cell permeable p18 recombinant protein as an effective ingredient. The cell permeable p18 recombinant proteins of the present invention are capable of efficiently introducing a haploinsufficient tumor suppressor p18 into a cell, and thus, can activate cell signaling mechanisms involved in the activation of ATM and p53 that induce cell cycle arrest and apoptosis in response to DNA damage or oncogenic signals. Therefore, the cell permeable p18 recombinant proteins of the present invention can be effectively used as an anticancer agent.Type: ApplicationFiled: September 4, 2008Publication date: December 2, 2010Applicant: Procell Therapeutics Inc.Inventors: Daewoong Jo, Seolhwa Kim, Jung-Hee Lim, Kisuk Park, Se-Eun Kang
-
Publication number: 20100197598Abstract: The present invention discloses novel macromolecule transduction domain (MTD) peptides which facilitate the traverse of a biologically active molecule across the cell membrane. Also disclosed are polynucleotides encoding the MTD peptides, methods of identifying the MTD peptides; methods of genetically engineering a biologically active molecule to have cell permeability by using the MTD peptides, methods of importing a biologically active molecule into a cell by using the MTD peptides, and uses thereof.Type: ApplicationFiled: January 29, 2008Publication date: August 5, 2010Applicant: PROCELL THERAPEUTICS INCInventors: Dae Woong Jo, Jae Sun Ko, Jin Sook Kim, Kyung Mi Park, Jin Kyung Song, Jung Hee Lim, Thi Thuy Nga Do, Thi Lan Phuong Do, Minh Tam Duong
-
Publication number: 20100099144Abstract: The present invention discloses cell permeable Nanog and Oct4 recombinant proteins that comprise a kaposi fibroblast growth factor 4 (kFGF4)-derived macromolecule transduction domain (MTD). Also disclosed are polynucleotides encoding the cell permeable Nanog and Oct4 recombinant proteins, a method of increasing self-renewal and suppressing differentiation of stem cells by treating the cells in combination with the cell permeable Nanog and Oct4 recombinant proteins, and the combined use of the cell permeable Nanog and Oct4 recombinant proteins for increasing self-renewal and suppressing differentiation of stem cells.Type: ApplicationFiled: February 27, 2008Publication date: April 22, 2010Applicant: PROCELL THERAPEUTICS INC.Inventors: Dae Woong Jo, Jin Sook Kim, Yun Kyung Park